Literature DB >> 19396154

Prostate cancer of transition zone origin lacks TMPRSS2-ERG gene fusion.

Charles C Guo1, Geyan Zuo, Dongdong Cao, Patricia Troncoso, Bogdan A Czerniak.   

Abstract

Recent studies have shown a unique chromosomal rearrangement that leads to the fusion of 5'-transmembrane protein serine proteinase-2 (TMPRSS2) with the EST-related gene (ERG) in prostate cancer. In this study, we used fluorescence in situ hybridization to evaluate TMPRSS2-ERG gene fusion in prostate cancer of different zonal origins. Radical prostatectomy specimens with multifocal prostate cancer were obtained from 30 patients who were treated at our institution. Two separate tumor foci in each specimen, one in the peripheral zone and the other in the transition zone, were selected for gene fusion analysis. The selected peripheral zone tumor foci had a mean Gleason score of 6.8 (range, 6-7) and a mean tumor volume of 1.2 cm(3) (range, 0.1-4.6 cm(3)). The selected transition zone tumor foci had a mean Gleason score of 6.7 (range, 5-8) and a mean tumor volume of 4.0 cm(3) (range, 0.5-9.0 cm(3)). ERG gene rearrangement was not observed in any transition zone tumors; however, it was found in the peripheral zone tumors in 13 cases (43%). In 10 cases, the rearrangement was associated with the deletion of the 5'-end of ERG. In conclusion, we found that TMPRSS2-ERG gene fusion is associated with the zonal origin of prostate cancer. This gene fusion is prevalent in prostate cancer arising from the peripheral zone, but is lacking in prostate cancer arising from the transition zone.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19396154     DOI: 10.1038/modpathol.2009.57

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  21 in total

1.  The relationship of TMPRSS2-ERG gene fusion between primary and metastatic prostate cancers.

Authors:  Charles C Guo; Yan Wang; Li Xiao; Patricia Troncoso; Bogdan A Czerniak
Journal:  Hum Pathol       Date:  2011-09-19       Impact factor: 3.466

2.  Molecular sampling of prostate cancer: a dilemma for predicting disease progression.

Authors:  Andrea Sboner; Francesca Demichelis; Stefano Calza; Yudi Pawitan; Sunita R Setlur; Yujin Hoshida; Sven Perner; Hans-Olov Adami; Katja Fall; Lorelei A Mucci; Philip W Kantoff; Meir Stampfer; Swen-Olof Andersson; Eberhard Varenhorst; Jan-Erik Johansson; Mark B Gerstein; Todd R Golub; Mark A Rubin; Ove Andrén
Journal:  BMC Med Genomics       Date:  2010-03-16       Impact factor: 3.063

3.  Molecular differences in transition zone and peripheral zone prostate tumors.

Authors:  Jennifer A Sinnott; Jennifer R Rider; Jessica Carlsson; Travis Gerke; Svitlana Tyekucheva; Kathryn L Penney; Howard D Sesso; Massimo Loda; Katja Fall; Meir J Stampfer; Lorelei A Mucci; Yudi Pawitan; Sven-Olof Andersson; Ove Andrén
Journal:  Carcinogenesis       Date:  2015-04-13       Impact factor: 4.944

4.  TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate.

Authors:  Charles C Guo; Jane Y Dancer; Yan Wang; Ana Aparicio; Nora M Navone; Patricia Troncoso; Bogdan A Czerniak
Journal:  Hum Pathol       Date:  2010-10-30       Impact factor: 3.466

5.  PTEN loss and ERG protein expression are infrequent in prostatic ductal adenocarcinomas and concurrent acinar carcinomas.

Authors:  Carlos L Morais; Mehsati Herawi; Antoun Toubaji; Roula Albadine; Jessica Hicks; George J Netto; Angelo M De Marzo; Jonathan I Epstein; Tamara L Lotan
Journal:  Prostate       Date:  2015-07-14       Impact factor: 4.104

6.  The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis.

Authors:  Andreas Pettersson; Rebecca E Graff; Scott R Bauer; Michael J Pitt; Rosina T Lis; Edward C Stack; Neil E Martin; Lauren Kunz; Kathryn L Penney; Azra H Ligon; Catherine Suppan; Richard Flavin; Howard D Sesso; Jennifer R Rider; Christopher Sweeney; Meir J Stampfer; Michelangelo Fiorentino; Philip W Kantoff; Martin G Sanda; Edward L Giovannucci; Eric L Ding; Massimo Loda; Lorelei A Mucci
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-06-26       Impact factor: 4.254

Review 7.  Genomic and phenotypic heterogeneity in prostate cancer.

Authors:  Michael C Haffner; Wilbert Zwart; Martine P Roudier; Lawrence D True; William G Nelson; Jonathan I Epstein; Angelo M De Marzo; Peter S Nelson; Srinivasan Yegnasubramanian
Journal:  Nat Rev Urol       Date:  2020-12-16       Impact factor: 14.432

8.  Studies of TMPRSS2-ERG gene fusions in diagnostic trans-rectal prostate biopsies.

Authors:  Gerhardt Attard; Johann S de Bono; Jeremy Clark; Colin S Cooper
Journal:  Clin Cancer Res       Date:  2010-02-09       Impact factor: 12.531

9.  Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: morphological, immunohistochemical, and gene expression profiles.

Authors:  Nora M Navone; Sankar N Maity; Ana Aparicio; Vasiliki Tzelepi; John C Araujo; Charles C Guo; Shoudan Liang; Patricia Troncoso; Christopher J Logothetis
Journal:  Prostate       Date:  2010-11-17       Impact factor: 4.104

10.  TMPRSS2-ERG rearrangement in dominant anterior prostatic tumours: incidence and correlation with ERG immunohistochemistry.

Authors:  Anuradha Gopalan; Margaret A Leversha; Maria E Dudas; Alexandra C Maschino; Jeremy Chang; Hikmat A Al-Ahmadie; Ying-Bei Chen; Satish K Tickoo; Victor E Reuter; Samson W Fine
Journal:  Histopathology       Date:  2013-05-23       Impact factor: 5.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.